Baraliakos Xenofon, Gladman Dafna D, Chakravarty Soumya D, Gong Cinty, Shawi May, Rampakakis Emmanouil, Kishimoto Mitsumasa, Soriano Enrique R, Mease Philip J
Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany.
Department of Medicine, University of Toronto, Schroeder Arthritis Institute; Krembil, Research Institute; Toronto Western Hospital, Toronto, ON, Canada.
Rheumatol Adv Pract. 2024 Apr 23;8(2):rkae058. doi: 10.1093/rap/rkae058. eCollection 2024.
In the absence of axial psoriatic arthritis (axPsA)-specific tools, the BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) are used to assess axial symptoms in patients with PsA. Here, we assessed the performance of BASDAI and ASDAS in patients with PsA.
Patients with active PsA in DISCOVER-1 and DISCOVER-2 (ClinicalTrials.gov: NCT03162796 and NCT03158285, respectively) with or without axPsA but with available baseline BASDAI information were analysed; those with investigator-identified axial symptoms and imaging-confirmed sacroiliitis comprised the axPsA cohort. Correlations between BASDAI/ASDAS and clinical variables were assessed with Pearson's coefficient (). Longitudinal effects of enthesitis (Leeds Enthesitis Index [LEI]), swollen joint count and presence versus absence of axPsA on BASDAI/ASDAS (normalized 0-10 scale) were analysed with mixed models for repeated measures.
At baseline in the axPsA ( = 312) and non-axPsA ( = 124) cohorts, BASDAI scores showed no or weak correlation with swollen joint count (0.18-0.20), tender joint count (0.12-0.29), LEI (-0.04 to 0.24) and physician global assessment (0.35-0.43); moderate correlation with fatigue (both -0.56); and strong correlation with patient global assessment of disease activity (0.62-0.69) and patient-reported pain (0.66-0.70). Similar correlations were observed for ASDAS. Axial involvement versus non-involvement was associated with higher BASDAI scores and ASDAS (all β ≥ 0.5), without differences between instruments; longitudinal associations between swollen joint count (β ≤ 0.06)/LEI (β ≤ 0.19) and BASDAI/ASDAS were clinically unimportant.
BASDAI and ASDAS performed similarly in patients with active PsA and axial involvement, independent of peripheral disease involvement, supporting their performance in assessing axial disease activity.
ClinicalTrials.gov, http://clinicaltrials.gov, NCT03162796 and NCT03158285.
在缺乏轴性银屑病关节炎（axPsA）特异性工具的情况下，巴氏强直性脊柱炎疾病活动指数（BASDAI）和强直性脊柱炎疾病活动评分（ASDAS）被用于评估银屑病关节炎（PsA）患者的轴性症状。在此，我们评估了BASDAI和ASDAS在PsA患者中的表现。
分析了DISCOVER-1和DISCOVER-2研究（ClinicalTrials.gov标识符分别为NCT03162796和NCT03158285）中患有活动性PsA、有或无axPsA但有可用基线BASDAI信息的患者；那些有研究者确定的轴性症状且影像学证实有骶髂关节炎的患者组成axPsA队列。用Pearson相关系数评估BASDAI/ASDAS与临床变量之间的相关性。用重复测量的混合模型分析附着点炎（利兹附着点炎指数[LEI]）、肿胀关节计数以及是否存在axPsA对BASDAI/ASDAS（标准化0-10分制）的纵向影响。
在axPsA队列（n = 312）和非axPsA队列（n = 124）的基线时，BASDAI评分与肿胀关节计数（0.18 - 0.20）、压痛关节计数（0.12 - 0.29）、LEI（-0.04至0.24）和医生整体评估（0.35 - 0.43）无或仅有微弱相关性；与疲劳（两者均为-0.56）有中度相关性；与患者对疾病活动的整体评估（0.62 - 0.69）和患者报告的疼痛（0.66 - 0.70）有强相关性。ASDAS也观察到类似的相关性。有轴性受累与无轴性受累相比，BASDAI评分和ASDAS更高（所有β≥0.5），不同工具之间无差异；肿胀关节计数（β≤0.06）/LEI（β≤0.19）与BASDAI/ASDAS之间的纵向关联在临床上无重要意义。
BASDAI和ASDAS在有活动性PsA和轴性受累的患者中表现相似，与外周疾病受累无关，支持它们在评估轴性疾病活动方面的表现。
ClinicalTrials.gov，http://clinicaltrials.gov，NCT03162796和NCT03158285。
